Aurobindo Pharma announced the acquisition of Lannett Company LLC in the United States through its wholly owned subsidiary, Aurobindo Pharma USA Inc. The move provides Aurobindo with a critical U.S.-based manufacturing base at a time when concerns around tariffs on pharmaceutical imports are mounting.
Expanding Capabilities with a Robust U.S. Facility
Lannett, headquartered in Trevose, Pennsylvania, is a well-established manufacturer and supplier of complex generic pharmaceuticals, including DEA-controlled substances. The facility currently operates at 40% capacity, producing four billion annual doses, with ample room for expansion. It offers a purpose-built infrastructure that enables rapid scale-up, allowing Aurobindo to meet growing U.S. demand and reduce reliance on Indian exports.
With a strong compliance track record with both the U.S. FDA and DEA, the facility supports a nimble and diversified product portfolio, especially in the area of non-opioid controlled substances with high regulatory and technical complexity.
Aligning with U.S. Reshoring and Government Priorities
U.S.-based manufacturing footprint gives Aurobindo a strategic edge in aligning with government reshoring initiatives and preferences in public procurement. The acquisition not only reduces exposure to tariff risks but also opens up new government business opportunities, positioning the company as a preferred local supplier in the U.S. pharmaceutical landscape.
Access to European Markets and Export Expansion
Beyond the U.S. market, the facility offers Aurobindo potential access to European export markets through local manufacturing. The geographic diversification enhances the company’s global supply resilience while maintaining compliance with international standards.
Operational Synergies and Cost Efficiency
The acquisition also unlocks significant cost synergies through SG&A rationalisation and operational leverage. By utilising the currently underutilised capacity at the U.S. site, Aurobindo can scale production volumes, thereby lowering unit costs and enhancing profitability. The addition of over 430 experienced employees further strengthens the company’s technical and regulatory capabilities.
Expert Perspective: A Timely and Tactical Acquisition
R Uday Bhaskar, former Director-General, Pharmexcil, noted, “The new manufacturing base in the U.S. will allow Aurobindo to offset any adverse impact of tariffs on imports from India through local production, besides providing access to the European export market.”
